Risk of Secondary Infections in Patients Hospitalized for Coronavirus Disease 2019: Univariate and Multivariate Analyses
| Parameters by Model Type . | OR (95% CI) . | P Value . |
|---|---|---|
| Univariate model | ||
| Baricitinib + remdesivir treatment arm | 0.50 (.31–.79) | .003 |
| No. of coexisting health conditions | ||
| 1 | 0.99 (.51–1.94) | .98 |
| ≥2 | 0.78 (.42–1.45) | .44 |
| Age group | ||
| 40–64 y | 1.76 (.85–3.66) | .13 |
| ≥65 y | 1.92 (.89–4.16) | .10 |
| Use of ≥1 immunosuppressant | 1.56 (.79–3.05) | .20 |
| Multivariate model | ||
| Baricitinib + remdesivir treatment arm and age group | 0.50 (.31–.79) | .003 |
| Parameters by Model Type . | OR (95% CI) . | P Value . |
|---|---|---|
| Univariate model | ||
| Baricitinib + remdesivir treatment arm | 0.50 (.31–.79) | .003 |
| No. of coexisting health conditions | ||
| 1 | 0.99 (.51–1.94) | .98 |
| ≥2 | 0.78 (.42–1.45) | .44 |
| Age group | ||
| 40–64 y | 1.76 (.85–3.66) | .13 |
| ≥65 y | 1.92 (.89–4.16) | .10 |
| Use of ≥1 immunosuppressant | 1.56 (.79–3.05) | .20 |
| Multivariate model | ||
| Baricitinib + remdesivir treatment arm and age group | 0.50 (.31–.79) | .003 |
Abbreviations: CI, confidence interval; OR, odds ratio.
Risk of Secondary Infections in Patients Hospitalized for Coronavirus Disease 2019: Univariate and Multivariate Analyses
| Parameters by Model Type . | OR (95% CI) . | P Value . |
|---|---|---|
| Univariate model | ||
| Baricitinib + remdesivir treatment arm | 0.50 (.31–.79) | .003 |
| No. of coexisting health conditions | ||
| 1 | 0.99 (.51–1.94) | .98 |
| ≥2 | 0.78 (.42–1.45) | .44 |
| Age group | ||
| 40–64 y | 1.76 (.85–3.66) | .13 |
| ≥65 y | 1.92 (.89–4.16) | .10 |
| Use of ≥1 immunosuppressant | 1.56 (.79–3.05) | .20 |
| Multivariate model | ||
| Baricitinib + remdesivir treatment arm and age group | 0.50 (.31–.79) | .003 |
| Parameters by Model Type . | OR (95% CI) . | P Value . |
|---|---|---|
| Univariate model | ||
| Baricitinib + remdesivir treatment arm | 0.50 (.31–.79) | .003 |
| No. of coexisting health conditions | ||
| 1 | 0.99 (.51–1.94) | .98 |
| ≥2 | 0.78 (.42–1.45) | .44 |
| Age group | ||
| 40–64 y | 1.76 (.85–3.66) | .13 |
| ≥65 y | 1.92 (.89–4.16) | .10 |
| Use of ≥1 immunosuppressant | 1.56 (.79–3.05) | .20 |
| Multivariate model | ||
| Baricitinib + remdesivir treatment arm and age group | 0.50 (.31–.79) | .003 |
Abbreviations: CI, confidence interval; OR, odds ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
